Syndax Pharmaceuticals SNDX Business Segments — Cost Of Product Sales

Similar metrics at other companies

PFEBiopharma — Cost of Sales

$3.03B+31.1%

BAXMedical Products & Therapies — Cost of Sales

$781M+12.5%

BAXPharmaceuticals — Cost of Sales

$458M+15.7%

TVTXTotal net product sales — Cost of goods sold

$1.95M+55.6%

ARDXProduct sales, net — Cost of Sales

$2.88M+22.9%

MIRMCost of Sales

$28.81M+25.1%

Questions, answered.

What is Syndax Pharmaceuticals's business segments — cost of product sales?

Syndax Pharmaceuticals (SNDX) reported business segments — cost of product sales of $2.63M in Q1 2026.

How has Syndax Pharmaceuticals's business segments — cost of product sales changed year-over-year?

Syndax Pharmaceuticals's business segments — cost of product sales increased by 197.5% year-over-year, from $885K to $2.63M.

What does business segments — cost of product sales mean?

This represents the direct costs incurred to manufacture and distribute pharmaceutical products sold within the cancer therapeutics segment. It includes raw materials, labor, and overhead directly attributable to the production process. Monitoring this metric helps assess the gross margin efficiency and the scalability of the company's manufacturing operations.